[go: up one dir, main page]

WO2000023057A3 - Atypical antiphsychotic in combination with acetylcholinesterase inhibitor for improving cognition - Google Patents

Atypical antiphsychotic in combination with acetylcholinesterase inhibitor for improving cognition Download PDF

Info

Publication number
WO2000023057A3
WO2000023057A3 PCT/EP1999/007804 EP9907804W WO0023057A3 WO 2000023057 A3 WO2000023057 A3 WO 2000023057A3 EP 9907804 W EP9907804 W EP 9907804W WO 0023057 A3 WO0023057 A3 WO 0023057A3
Authority
WO
WIPO (PCT)
Prior art keywords
acetylcholinesterase inhibitor
atypical
antiphsychotic
combination
improving cognition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1999/007804
Other languages
French (fr)
Other versions
WO2000023057A2 (en
Inventor
Nijs Paul Leonce Irma De
Wim Louis Julien Parys
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2000576832A priority Critical patent/JP2002527469A/en
Priority to EEP200100136A priority patent/EE200100136A/en
Priority to BR9914419-0A priority patent/BR9914419A/en
Priority to CA002345767A priority patent/CA2345767A1/en
Priority to SK459-2001A priority patent/SK4592001A3/en
Priority to HU0103781A priority patent/HUP0103781A3/en
Priority to HK02100158.6A priority patent/HK1039745A1/en
Priority to IL14258899A priority patent/IL142588A0/en
Priority to KR1020017002286A priority patent/KR20010072878A/en
Priority to AU64727/99A priority patent/AU6472799A/en
Priority to EP99952580A priority patent/EP1121131A2/en
Priority to HR20010262A priority patent/HRP20010262A2/en
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Priority to PL99348107A priority patent/PL348107A1/en
Publication of WO2000023057A2 publication Critical patent/WO2000023057A2/en
Publication of WO2000023057A3 publication Critical patent/WO2000023057A3/en
Priority to BG105302A priority patent/BG105302A/en
Priority to NO20011403A priority patent/NO20011403D0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention is concerned with pharmaceutical compositions comprising a carrier and as first active ingredient an atypical antipsychotic agent (I) and as second active ingredient an acetylcholinesterase inhibitor (II), each in an amount producing a therapeutically beneficial effect in patients suffering from psychosis, or Alzheimer's disease or related dementias. Said therapeutically beneficial effect can be a synergistic effect on the cognitive functioning of patients suffering from Alzheimer's disease or related dementias or the prevention of the further deterioration of cognition in said patients, or the reduction of adverse effects associated with the one of the active ingredients by the other of the active ingredients.
PCT/EP1999/007804 1998-10-16 1999-10-12 Atypical antiphsychotic in combination with acetylcholinesterase inhibitor for improving cognition Ceased WO2000023057A2 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
EEP200100136A EE200100136A (en) 1998-10-16 1999-10-12 Use of an acetylcholine esterase inhibitor and an antipsychotic agent in the manufacture of a medicament for the treatment of cognitive and psychotic disorders, and a pharmaceutical composition containing these agents
BR9914419-0A BR9914419A (en) 1998-10-16 1999-10-12 Perception improvement therapy
CA002345767A CA2345767A1 (en) 1998-10-16 1999-10-12 Therapy for improving cognition
SK459-2001A SK4592001A3 (en) 1998-10-16 1999-10-12 Atypical antipsychotic in combination with acetylcholinesterase inhibitor for improving cognition
HU0103781A HUP0103781A3 (en) 1998-10-16 1999-10-12 Pharmaceutical compositions comprising atypical antiphsychotic agent in combination with acetylcholinesterase inhibitor for improving cognition
HK02100158.6A HK1039745A1 (en) 1998-10-16 1999-10-12 Atypical antipsychotic in combination with acetylcholinesterase inhibitor for improving cognition
IL14258899A IL142588A0 (en) 1998-10-16 1999-10-12 Therapy for improving cognition
AU64727/99A AU6472799A (en) 1998-10-16 1999-10-12 Therapy for improving cognition
KR1020017002286A KR20010072878A (en) 1998-10-16 1999-10-12 Atypical antiphsychotic in combination with acetylcholinesterase inhibitor for improving cognition
JP2000576832A JP2002527469A (en) 1998-10-16 1999-10-12 Therapy to improve cognition
HR20010262A HRP20010262A2 (en) 1998-10-16 1999-10-12 Therapy for improving cognition
EP99952580A EP1121131A2 (en) 1998-10-16 1999-10-12 Atypical antipsychotic in combination with acetylcholinesterase inhibitor for improving cognition
PL99348107A PL348107A1 (en) 1998-10-16 1999-10-12 Therapy for improving cognition
BG105302A BG105302A (en) 1998-10-16 2001-03-01 Means for improving cognition
NO20011403A NO20011403D0 (en) 1998-10-16 2001-03-20 Therapy to improve congestion

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98203454.8 1998-10-16
EP98203454 1998-10-16

Publications (2)

Publication Number Publication Date
WO2000023057A2 WO2000023057A2 (en) 2000-04-27
WO2000023057A3 true WO2000023057A3 (en) 2000-07-27

Family

ID=8234219

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/007804 Ceased WO2000023057A2 (en) 1998-10-16 1999-10-12 Atypical antiphsychotic in combination with acetylcholinesterase inhibitor for improving cognition

Country Status (20)

Country Link
EP (1) EP1121131A2 (en)
JP (1) JP2002527469A (en)
KR (1) KR20010072878A (en)
CN (1) CN1367697A (en)
AU (1) AU6472799A (en)
BG (1) BG105302A (en)
BR (1) BR9914419A (en)
CA (1) CA2345767A1 (en)
EE (1) EE200100136A (en)
HK (1) HK1039745A1 (en)
HR (1) HRP20010262A2 (en)
HU (1) HUP0103781A3 (en)
ID (1) ID28441A (en)
IL (1) IL142588A0 (en)
NO (1) NO20011403D0 (en)
PL (1) PL348107A1 (en)
SK (1) SK4592001A3 (en)
TR (1) TR200101082T2 (en)
WO (1) WO2000023057A2 (en)
ZA (1) ZA200103081B (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006201188B2 (en) * 2001-02-05 2007-11-15 Novartis Ag New use of iloperidone
GB0102841D0 (en) * 2001-02-05 2001-03-21 Novartis Ag Organic compounds
CA2463158C (en) 2001-10-30 2013-07-30 Novartis Ag Depot formulations of iloperidone and a star polymer
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
US20040192754A1 (en) * 2003-03-24 2004-09-30 Shapira Nathan Andrew Methods for treating idiopathic hyperhidrosis and associated conditions
TW200501962A (en) * 2003-04-01 2005-01-16 Novartis Ag Use of carbamazepine derivatives for the treatment of agitation in dementia patients
WO2005065645A2 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Donepezil formulations
JP2008523058A (en) * 2004-12-10 2008-07-03 アボット・ラボラトリーズ Fused bicycloheterocyclic substituted quinuclidine derivatives
JP5379692B2 (en) 2006-11-09 2013-12-25 プロビオドルグ エージー 3-Hydroxy-1,5-dihydro-pyrrol-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcers, cancer and other diseases
DK2091948T3 (en) 2006-11-30 2012-07-23 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
AU2008220785B2 (en) 2007-03-01 2013-02-21 Vivoryon Therapeutics N.V. New use of glutaminyl cyclase inhibitors
US9656991B2 (en) 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
MX2007008642A (en) * 2007-07-16 2009-02-25 World Trade Imp Export Wtie Ag Pharmaceutical composition comprising the combination of a benzisoxazolic derived agent and a reversible inhibiting agent of the cholinesterase enzyme prescribed for the control and treatment of psychotic disorders and dementias.
CA2789014C (en) 2010-02-09 2019-01-15 Michela Gallagher Methods and compositions for improving cognitive function
JP6026284B2 (en) 2010-03-03 2016-11-16 プロビオドルグ エージー Inhibitors of glutaminyl cyclase
EA022420B1 (en) 2010-03-10 2015-12-30 Пробиодруг Аг Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
ES2570167T3 (en) 2011-03-16 2016-05-17 Probiodrug Ag Benzimidazole derivatives as glutaminyl cyclase inhibitors
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
CN105142623A (en) 2013-03-15 2015-12-09 艾吉因生物股份有限公司 Methods and compositions for improving cognitive function
JP6899043B2 (en) 2015-05-22 2021-07-07 エージンバイオ， インコーポレイテッド Sustained release pharmaceutical composition of levetiracetam
ES2812698T3 (en) 2017-09-29 2021-03-18 Probiodrug Ag Glutaminyl cyclase inhibitors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0515301A2 (en) * 1991-05-14 1992-11-25 Ernir Snorrason Improvements in benzodiazepine treatment by cholinesterterase inhibitors
EP0879596A2 (en) * 1991-05-14 1998-11-25 Ernir Snorasson Use of cholinesterase inhibitors to reduce benzodiazepine side effects
WO1999007378A1 (en) * 1997-08-11 1999-02-18 THE UNIVERSITY OF SOUTH FLORIDA A Corporation of the State of Florida Nicotine antagonists for nicotine-responsive neuropsychiatric disorders
WO1999052519A2 (en) * 1998-04-14 1999-10-21 The General Hospital Corporation Methods for treating neuropsychiatric disorders

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0515301A2 (en) * 1991-05-14 1992-11-25 Ernir Snorrason Improvements in benzodiazepine treatment by cholinesterterase inhibitors
EP0879596A2 (en) * 1991-05-14 1998-11-25 Ernir Snorasson Use of cholinesterase inhibitors to reduce benzodiazepine side effects
WO1999007378A1 (en) * 1997-08-11 1999-02-18 THE UNIVERSITY OF SOUTH FLORIDA A Corporation of the State of Florida Nicotine antagonists for nicotine-responsive neuropsychiatric disorders
WO1999052519A2 (en) * 1998-04-14 1999-10-21 The General Hospital Corporation Methods for treating neuropsychiatric disorders

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
FERNANDEZ H.H. ET AL: "Donepezil for Huntington's disease.", MOVEMENT DISORDERS, (2000) 15/1 (173-176)., XP000892632 *
GALASKO D: "A CLINICAL APPROACH TO DEMENTIA WITH LEWY BODIES", THE NEUROLOGIST, vol. 5, no. 5, September 1999 (1999-09-01), pages 247 - 257, XP000878694 *
GEIZER M. ET AL: "Combination of risperidone and donepezil in Lewy body dementia", CAN. J. PSYCHIATRY, May 1998 (1998-05-01), pages 421 - 422, XP000892680 *
KELLY J S: "Alzheimer's disease: the tacrine legacy", TRENDS IN PHARMACOLOGICAL SCIENCES,GB,ELSEVIER TRENDS JOURNAL, CAMBRIDGE, vol. 20, no. 4, April 1999 (1999-04-01), pages 127 - 129, XP004172560, ISSN: 0165-6147 *
MAGNUSON T M ET AL: "Extrapyramidal side effects in a patient treated with risperidone plus donepezil [letter].", AMERICAN JOURNAL OF PSYCHIATRY, (1998 OCT) 155 (10) 1458-9., XP000892634 *
MAZUREK A. A.: "Treatment of Alzheimer's disease", N ENG J. MED, vol. 342, no. 11, 16 March 2000 (2000-03-16), pages 821 - 822, XP000901026 *
MELTZER, H. Y. (1) ET AL: "Atypical antipsychotic drugs (APD) but not typical APD increased extracellular acetylcholine (ACh-ext) levels in rat medial prefrontal cortex (mPFC) in the absence AChEsterase (AChE) inhibition.", SOCIETY FOR NEUROSCIENCE ABSTRACTS, (1999) VOL. 25, NO. 1-2, PP. 452. MEETING INFO.: 29TH ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE, PART 1 MIAMI BEACH, FLORIDA, USA OCTOBER 23-28, 1999 THE SOCIETY FOR NEUROSCIENCE., XP000892699 *
SIMONSON W.: "Promising agents for treating Alzheimer's disease.", AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, (1 NOV 1998) 55/21 SUPPL. (S11-S16)., XP002134583 *
YAQUB B.A.: "New horizons in management of Alzheimer 's disease.", SAUDI MEDICAL JOURNAL, (1999) 20/9 (671-677)., XP000892838 *

Also Published As

Publication number Publication date
HRP20010262A2 (en) 2002-06-30
JP2002527469A (en) 2002-08-27
NO20011403L (en) 2001-03-20
PL348107A1 (en) 2002-05-06
ID28441A (en) 2001-05-24
CN1367697A (en) 2002-09-04
CA2345767A1 (en) 2000-04-27
BG105302A (en) 2001-11-30
EE200100136A (en) 2002-06-17
AU6472799A (en) 2000-05-08
EP1121131A2 (en) 2001-08-08
BR9914419A (en) 2001-06-26
HUP0103781A3 (en) 2003-09-29
KR20010072878A (en) 2001-07-31
TR200101082T2 (en) 2001-09-21
IL142588A0 (en) 2002-03-10
NO20011403D0 (en) 2001-03-20
SK4592001A3 (en) 2001-12-03
HK1039745A1 (en) 2002-05-10
HUP0103781A2 (en) 2002-03-28
WO2000023057A2 (en) 2000-04-27
ZA200103081B (en) 2002-07-12

Similar Documents

Publication Publication Date Title
WO2000023057A3 (en) Atypical antiphsychotic in combination with acetylcholinesterase inhibitor for improving cognition
CA2370565A1 (en) Dermally applicable vitamin d-containing pharmaceutical compositions
CA2326756A1 (en) Pharmaceutical compositions containing compounds with activity for the enhancement of absorption of active ingredients
CA2183972A1 (en) Oxazolidinone derivatives and pharmaceutical compositions containing them
CA2356380A1 (en) Immunosuppressive effects of pteridine derivatives
CA2317044A1 (en) Medicament for neurodegenerative diseases
WO2002042462A3 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
GEP20033131B (en) Azabicycloalkanes as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Activity
WO1999063977A3 (en) Pharmaceutical combination comprising a tricyclic compound and at least one of zolpidem, zopiclone, triazolam and brotizolam for treating or preventing sleep disorders
MXPA02000437A (en) Composition for treatment of external secretion disorders.
CA2214026A1 (en) Pharmaceutical compositions comprising monoamine oxidase b inhibitors
BR0012696A (en) Ophthalmic composition
MXPA02002452A (en) Preventive and therapeutic agents for eye diseases.
HUP0204049A3 (en) Compositions of combined active ingredients for treating glaucoma
EP2138175A3 (en) Formulations comprising valsartan for treating diabetes or microalbuminuria
IL159412A0 (en) A synergistic pharmaceutical combination for the prevention or treatment of diabetes
CA2282279A1 (en) Atropisomers of 3-heteroaryl-4(3h)-quinazolinones for the treatment of neurodegenerative and cns-trauma related conditions
WO1999061010A3 (en) Treatment of infertility with cam-increasing compounds alone or in combination with at least one meiosis-stimulating compound
TW354762B (en) Agent for prophylaxis or treatment of cataract
CA2192822A1 (en) Use of immunosuppressive agents for the treatment of schizophrenia
IL113706A0 (en) N-hydroxyureas as antiinflammatory agents
EP0842663A4 (en) Ophthalmic preparations
WO2001005386A3 (en) Pharmaceutical composition useful for the treatment of tinnitus and hearing loss
EP1121932A4 (en) Remedies for ocular diseases
LT96094A (en) The active ingredient of pharmaceutical composition for treating constipation

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99812184.3

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 1999 64727

Country of ref document: AU

Kind code of ref document: A

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1999952580

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1200100147

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 510015

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1020017002278

Country of ref document: KR

Ref document number: 1020017002286

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 1999 105302

Country of ref document: BG

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2345767

Country of ref document: CA

Ref document number: 2345767

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2001/00354/MU

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: PV2001-1211

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 4592001

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 09807160

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: P20010262A

Country of ref document: HR

ENP Entry into the national phase

Ref document number: 2000 576832

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2001/03081

Country of ref document: ZA

Ref document number: 200103081

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2001/01082

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 142588

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/003835

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 64727/99

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: PV2001-1211

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1020017002286

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1999952580

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWR Wipo information: refused in national office

Ref document number: 1020017002278

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1020017002278

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1999952580

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1020017002286

Country of ref document: KR